Related Experiment Video

Updated: Jun 24, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma

L N Kaliberova1, V Krendelchtchikova, D K Harmon

  • 1Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35294-6832, USA. kalibero@uab.edu

Cancer Gene Therapy
|April 14, 2009
PubMed

Insights

Combining oncolytic virotherapy with vascular endothelial growth factor receptor 1 (VEGFR-1) conditional replicating adenoviral vectors and temozolomide (TMZ) chemotherapy shows promise for treating malignant glioma. This combination therapy enhanced cancer cell death and improved survival in preclinical models.

Area of Science:

  • Oncology
  • Gene Therapy
  • Virology

Background:

  • Malignant glioma, a common primary brain tumor, exhibits poor response to current therapies.
  • Key challenges in glioma treatment include suppressed apoptosis and high invasiveness.
  • Novel therapeutic strategies are needed to overcome treatment resistance in glioma.

Purpose of the Study:

  • To evaluate the efficacy of a combined therapeutic approach for human glioma.
  • To investigate the synergistic effects of oncolytic virotherapy and temozolomide (TMZ) chemotherapy.
  • To assess the impact of a novel vascular endothelial growth factor receptor 1 (VEGFR-1) conditional replicating adenoviral vector (CRAdRGDflt-IL24) encoding interleukin-24 (IL-24) in combination with TMZ.

Main Methods:

  • Development of a CRAdRGDflt-IL24 vector encoding the IL-24 gene.
  • In vitro assessment of cytotoxicity against human glioma cells using CRAdRGDflt-IL24 and TMZ, alone and in combination.
  • In vivo evaluation of tumor growth inhibition and survival in mice with intracranial human glioma xenografts.

Main Results:

  • The combination of CRAdRGDflt-IL24 and TMZ significantly enhanced cytotoxicity in vitro compared to monotherapy.
  • Combined treatment effectively inhibited D54MG tumor growth in vivo.
  • CRAdRGDflt-IL24 and TMZ combination therapy prolonged the survival of mice with intracranial human glioma xenografts.

Conclusions:

  • Combined oncolytic virotherapy using CRAdRGDflt-IL24 and TMZ chemotherapy presents a promising therapeutic strategy for malignant glioma.
  • This combination approach demonstrates enhanced efficacy in preclinical models.
  • Further investigation into this combined modality is warranted for clinical translation in glioma treatment.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...